A preclinical study led by investigators at the Vall d’Hebron Institute of Oncology has identified potential targeted therapy for pseudomyxoma peritonei, a rare cancer with limited treatment options. By generating patient-derived mouse models with druggable targets like KRAS and BRAF, researchers tested the efficacy of BRAF inhibitor encorafenib, showing promising results in reducing tumor growth and extending survival. This study represents a significant advancement towards personalized, molecularly matched treatments for patients with this disease. The next steps involve further validation in other models to explore the potential of KRAS inhibitors. This work was supported by the PMPnet Accelerator Award to advance research on pseudomyxoma peritonei.
Source link
Research may pave the way for systemic targeted therapy for patients with pseudomyxoma peritonei
